These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 11995208)

  • 1. [Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
    Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L
    Minerva Pediatr; 2000 Apr; 52(4):235-41. PubMed ID: 11995208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
    Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L
    J Pediatr Endocrinol Metab; 2000 Jun; 13(6):677-80. PubMed ID: 10905396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary embolism and intravenous high-dose desferrioxamine.
    Cianciulli P
    Haematologica; 1992; 77(4):368-9. PubMed ID: 1427452
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful desensitization of a case with desferrioxamine hypersensitivity.
    Gülen F; Demir E; Tanaç R; Aydinok Y; Gulen H; Yenigün A; Can D
    Minerva Pediatr; 2006 Dec; 58(6):571-4. PubMed ID: 17093379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short stature and body proportion in thalassaemia.
    Caruso-Nicoletti M; De Sanctis V; Capra M; Cardinale G; Cuccia L; Di Gregorio F; Filosa A; Galati MC; Lauriola A; Malizia R; Mangiagli A; Massolo F; Mastrangelo C; Meo A; Messina MF; Ponzi G; Raiola G; Ruggiero L; Tamborino G; Saviano A
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():811-6. PubMed ID: 10091151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine.
    De Sanctis V; Stea S; Savarino L; Scialpi V; Traina GC; Chiarelli GM; Sprocati M; Govoni R; Pezzoli D; Gamberini R; Rigolin F
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():827-33. PubMed ID: 10091153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful desensitization of a child with desferrioxamine hypersensitivity.
    Patriarca G; Schiavino D; Nucera E; Pellegrino S; Valle D; Della Corte AM; Pagliari G
    J Investig Allergol Clin Immunol; 1995; 5(5):294-5. PubMed ID: 8574439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of iron chelator desferrioxamine on serum zinc levels in patients with beta thalassemia major.
    Sultan S; Irfan SM; Kakar J; Zeeshan R
    Malays J Pathol; 2015 Apr; 37(1):35-8. PubMed ID: 25890611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative evaluation of the retinal venous tortuosity in chronic anaemic patients affected by beta-thalassaemia major.
    Incorvaia C; Parmeggiani F; Costagliola C; Perri P; D'Angelo S; Sebastiani A
    Eye (Lond); 2003 Apr; 17(3):324-9. PubMed ID: 12724693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.
    Thio D; Prasad V; Anslow P; Lennox P
    J Laryngol Otol; 2008 Nov; 122(11):1253-6. PubMed ID: 17931455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G; Koussi A; Economou M; Tsatra I; Perifanis V; Noussios G; Athanassiou-Metaxa M
    Acta Otorhinolaryngol Belg; 2004; 58(2):113-7. PubMed ID: 15515654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferiprone for thalassemia major.
    Rajeshwari K
    Indian Pediatr; 1999 Jul; 36(7):738-40. PubMed ID: 11203460
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results].
    Sacco M; Meleleo D; Tricarico N; Greco Miani A; Serra E; Parlatore L
    Minerva Pediatr; 1994 May; 46(5):225-30. PubMed ID: 8090141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute renal failure following deferoxamine overdose.
    Li Volti S; Maccarone C; Li Volti G; Romeo MA
    Pediatr Nephrol; 2003 Oct; 18(10):1078-9. PubMed ID: 12920634
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hepatic abscess due to Yersinia in a child with thalassemia].
    Brunel F; François P; Durand C; Croize J; Jeannoel P
    Pediatrie; 1993; 48(2):159-62. PubMed ID: 8393182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.